Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decline in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 9,500 shares, a decrease of 67.2% from the October 31st total of 29,000 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on APRE shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Monday, November 18th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now directly owns 44,730 shares in the company, valued at approximately $119,876.40. This represents a 28.79 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Marc Duey bought 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $4.39 per share, with a total value of $131,700.00. Following the completion of the purchase, the director now owns 240,113 shares in the company, valued at approximately $1,054,096.07. The trade was a 14.28 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 42,290 shares of company stock worth $165,096. Insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock traded up $0.01 on Wednesday, reaching $2.98. The company’s stock had a trading volume of 15,193 shares, compared to its average volume of 19,983. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The company has a market cap of $16.18 million, a price-to-earnings ratio of -1.06 and a beta of 0.97. The business’s fifty day moving average price is $3.31 and its 200 day moving average price is $3.77.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.